Methods of treating schizophrenia

Details Methods of treating schizophrenia Methods of treating schizophrenia

2006-10-03

2006-10-03

Falk, Anne-Marie (Department: 1632)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Reexamination Certificate

active

07115256

ABSTRACT:
The invention provides methods for the treatment of abnormal psychiatric states, particularly the negative symptoms of schizophrenia and extrapyramidal side effects (EPS) of antipsychotic drugs. The inventive methods relate to the administration of therapeutic cells (which produce dopamine or dopamine precursors) adhered to support matrices to subjects suffering from the negative symptoms of schizophrenia and/or EPS. The therapeutic cells may be coadministered with cells which protect the therapeutic cells from immune rejection and/or cells which produce neurotrophic factors which improve the viability of the therapeutic cells.

REFERENCES:
patent: 4935365 (1990-06-01), Nilsson et al.
patent: 5447948 (1995-09-01), Seibyl et al.
patent: 5618531 (1997-04-01), Cherksey
patent: 5650148 (1997-07-01), Gage et al.
patent: 5725854 (1998-03-01), Selawry
patent: 5750103 (1998-05-01), Cherksey
patent: WO 98/56393 (1998-12-01), None
patent: WO-99/34834 (1999-07-01), None
National Institute of Mental Health, Schizophrenia, Jun. 1, 1999.
Friedmann, T. Overcoming the obstacles to gene therapy. Sci. Am., Jun. 1997, pp. 96-101.
Jackowski, A. Neural injury repair: hope for the future as barriers to effective CNS regeneration become clearer. Br. J. Neurosurgery 9: 303-317.
Orkin and Motulsky. Report and recommendations of the panel to assess the NIH investment in research on gene therapy. Dec. 7, 1995.
Verma et al. (1997) Gene therapy—promises, problems and prospects. Nature 389: 239-242.
Bodkin, J.A. et al. (1996). “Treatment of Negative Symptoms in Schizophrenia and Schizoaffective Disorder by Selegiline Augmentation of Antipsychotic Medication: A Pilot Study Examining the Role of Dopamine,”Journal of Nervous and Mental Disease184(5): 295-301.
Andreasen, (1999). “Understanding the causes of schizophrenia,”New Eng. J. Med.340, No. 8, 645-647.
Angrist et al. (1992). “Central nervous system stimulants as symptomatic treatments for AIDS-related neuropsychiatric impairment,”J Clin. Psychopharm. 12 No. 4, 268-272.
Animal Cell Culture. Edited by: Freshney, R. I., 1987 (Table of Contents).
Antibodies: A Laboratory ManualEdited by: Harlow et al., 1987. (Table of Contents).
Benoist et al. (1981). “In vivosequence requirements of the SV40 early promoter region,”Nature290, 304-310.
Bohn et al. (1982). “Expression of phenylethanolamine N-methyltransferase in rat sympathetic ganglia and extra-adrenal chromaffin tissue,”Dev. Biol. 89, 299-308.
Current Protocols in Molecular Biology. Edited by: Ausubel, F. M. et al., 1987 (Table of Contents).
Daniel et al. (1989). “The effect of apomorphine in regional cerebral blood flow in schizophrenia,”J. Neuropsych. 1 No. 4, 377-384.
Daniel et al. (1991). “The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia,”J. Neurosci. 11 No. 7, 1907-1917.
Doering et al. (1984). “Isolation and transplantation of oligodendrocyte precursor cells,”J. Neurol. Sci. 63 No. 2, 183-196.
Eyre. (1980). “Collagen: molecular diversity in the body's protein scaffold,”Science207, 1315-1322.
Freed et al. (1981). “Transplanted adrenal chromaffin cells in rat brain reduce lesion-induced rotational behavior,”Nature292 No. 5281, 351-352.
Gage et al. (1987). “Grafting genetically modified cells to the brain: possibilities for the future,”Neurosci. 23 No. 3, 795-807.
Gash et al. (1986). “Amitotic neuroblastoma cells used for neural implants in monkeys,”Science233, 1420-1422.
Goldberg et al. (1994). “The effects of clozapine on neurocognition: an overview,”J. Clin. Psychiatry55:9 (suppl. B 88-90).
Greene e al. (1975). “Neuronal properties of hybrid neuroblasoma X sympathetic ganglion cells,”Proc. Natl. Acad. Sci. U.S.A.72 No. 12, 4923-4927.
Gross-Jendroska et al. (1990). “RPE-Stromal interactions modulate hyaluronic acid deposition: Role of HA-stimulating activity,”Investigative Opthamol. ARVO Suppl. 31, No. 4, 102.
Gumpel et al: (1984). “Survival and differentiation of oligodendrocytes from neural tissue transplanted into new-born mouse brain,”Neurosci. Lett. 37 No. 3, 307-311.
Gupta et al. (1985) “Differentiation characteristics of human neuroblastoma cells in the presence of growth modulators and antimitotic drugs,”Dev. Brain Res. 19, 21-29.
Hamer et al. (1982). “Regulationin vivoof a cloned mammalian gene: cadmium induces the transcription of a mouse metallothionein gene in SV40 vectors,”J. Mol. Appl. Genet. 1 No. 4, 273-288.
Jaffe et al. (1990). “Anti-transferrin receptor immunotoxin inhibits human RPE cell proliferation,”Investigative Opthamol. ARVO Suppl. 31, No. 4, 69.
Jentsch et al. (1997). “Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine,”Science277, 953-955.
Karlsson. et al. (1995), “Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients,”Psychopharmacology121, 309-316.
Keefe et al. (Sep. 1995). “A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spaial working memory in patients with schizophrenia,”Schizophr. Res. 17 No. 1, 25-33.
Kimhi et al. (1976). “Maturation of neuroblastome cells in the presence of dimethysulfoxide,”Proc. Natl. Acad. Sci. U. S. A. 73 No. 2, 462-466.
Kimhi.Excitable Cells in Tissue Culture. Edited by: Nelson, P. G. et al., New York: Plenum. 1977. 173-245.
Kovacic et al. (1982). “A monkey model of tardive dyskinesia (TD): evidence that reversible TD may turn into irreversible TD,”J. Clin. Psychopharmacol. 2 No. 5, 305-307.
Li et al. (1988). “Inherited retinal dystrophy in the RCS rat: prevention of photoreceptor degeneration by pigment epithelial transplantation,”Exp. Eye Res. 47 No. 6, 911-917.
Lopez et al. (1989). “Transplanted retinal pigment epithelium modifies the retinal degeneration in the RCS rat,”Invest. Ophthamol. Vis. Sci. 30 No. 3, 586-588.
Lui et al. (1990). “Stimulation of inositol phosphate formation in cultured human retinal pigment epithelial cells,”Investigative Opthamol. ARVO Suppl. 31, No. 4, 371.
Martin et al. (1985). “The genetically distinct collagens,”TIBS10, 285-287.
McKnight. (1982). “Fucntional relationships between transcriptional control signals of the thymidine kinase gene of herpes simplex virus,”Cell31(2 pt. 1), 355-365.
Methods in Enzymology. Edited by: Jakoby et al., 1979. (Table of Contents).
Moghaddam et al. (1997). “Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blcokade to dopaminergic and cognitive disruptions associated with the prefrontal cortex,”J. Neurosci. 17 No. 8, 2921-2927.
Moghaddam et al. (1998). “Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats,”Science281, 1349-1352.
Notter et al. (1986). “Neuronal properties of monkey adrenal medulla in vitro,”Cell Tiss. Res. 244 No. 1, 69-76.
Olson et al. (1980). “Chromaffine cells can innervate brain tissue: evidence from intraocular double grafts,”Exp. Neurol. 70 No. 2, 414-426.
Padgett et al. (1990). “Metalloproteinase and metallproteinase inhibitor secretion by human and RCS rat retinal pigment epithelium in culture,”Investigative Opthamol. ARVO Suppl. 31, No. 4, 72.
PCR 2: A Pratical Approach. Edited by: McPherson, M. J. et al., 1995. (Table of Contents).
Piercey et al. (1988). “Dramatic limbic and cortical effects mediated by high affinity PCP receptors,”Life Sci. 43 No. 4, 379-385.
Prasad et al. (1974) “Cyclic AMP and the differentiation of Neuroblastoma cells in culture,”Control of Proliferation in Animal Cells. Edited by: Clarkson, B. et al., Cold Spring Harbo

Affiliated with

Also associated with

Rating

Methods of treating schizophrenia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating schizophrenia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating schizophrenia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3719216